In June 2017, the Biotechnology Innovation Organization (BIO) released a set of principles on workforce development, diversity, and inclusion (WDDI) for the biotechnology industry. Concurrent with the adoption of these principles, BIO established a board-level WDDI Committee charged with working to foster workforce development, diversity, and inclusion at BIO and throughout the biotech industry. The Committee is chaired by Helen Torley, President & CEO of Halozyme, who succeeded Julie Gerberding, Executive Vice President & Chief Patient Officer at Merck, who led the Committee as it developed BIO’s WDDI principles over the last year.
Our mission is to create a more globally competitive biotechnology industry by promoting and enhancing workforce development, diversity, and inclusion.
Below are a list of resources available.
Half of his senior-most leadership team is made up of women, and 50 percent of his company’s total employees are female. The head of the largest U.S. bank on what it takes to transform the culture of an industry.
The BIO2017 Joanne Duncan, President of BIO’s Membership and Business Operations Division, discusses BIO's Workforce Development, Diversity, and Inclusion initiative.